190 related articles for article (PubMed ID: 28109130)
1. Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore-based virtual screening, molecular docking and molecular dynamics studies.
Islam MA; Pillay TS
Chem Biol Drug Des; 2017 Aug; 90(2):282-296. PubMed ID: 28109130
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore generation, atom-based 3D-QSAR and molecular dynamics simulation analyses of pyridine-3-carboxamide-6-yl-urea analogues as potential gyrase B inhibitors.
Azam MA; Thathan J
SAR QSAR Environ Res; 2017 Apr; 28(4):275-296. PubMed ID: 28399673
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Screening of DNA GyraseB Inhibitors for Therapeutic Applications in Tuberculosis: a Pharmacoinformatics Study.
Tambe PM; Bhowmick S; Chaudhary SK; Khan MR; Wabaidur SM; Muddassir M; Patil PC; Islam MA
Appl Biochem Biotechnol; 2020 Dec; 192(4):1107-1123. PubMed ID: 32686004
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
Maharaj Y; Soliman ME
Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
[TBL] [Abstract][Full Text] [Related]
5. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
Kashyap A; Singh PK; Silakari O
Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies.
Saxena S; Renuka J; Jeankumar VU; Yogeeswari P; Sriram D
Curr Top Med Chem; 2014; 14(17):1990-2005. PubMed ID: 25262795
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis.
Kashyap A; Singh PK; Satpati S; Verma H; Silakari O
J Cell Biochem; 2019 Mar; 120(3):3149-3159. PubMed ID: 30191589
[TBL] [Abstract][Full Text] [Related]
8. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
[TBL] [Abstract][Full Text] [Related]
9. Identification of promising anti-DNA gyrase antibacterial compounds using
Islam MA; Pillay TS
J Biomol Struct Dyn; 2020 Apr; 38(6):1798-1809. PubMed ID: 31084271
[TBL] [Abstract][Full Text] [Related]
10. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
[No Abstract] [Full Text] [Related]
11. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
Biochem Biophys Res Commun; 2014 Apr; 446(4):916-20. PubMed ID: 24642256
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Chaudhari K; Surana S; Jain P; Patel HM
Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
[TBL] [Abstract][Full Text] [Related]
13. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
[TBL] [Abstract][Full Text] [Related]
14. Identification of new DNA gyrase inhibitors based on bioactive compounds from streptomyces: structure-based virtual screening and molecular dynamics simulations approaches.
Kalhor H; Sadeghi S; Marashiyan M; Kalhor R; Aghaei Gharehbolagh S; Akbari Eidgahi MR; Rahimi H
J Biomol Struct Dyn; 2020 Feb; 38(3):791-806. PubMed ID: 30916622
[TBL] [Abstract][Full Text] [Related]
15. β-secretase inhibitors for Alzheimer's disease: identification using pharmacoinformatics.
Islam MA; Pillay TS
J Biomol Struct Dyn; 2019 Feb; 37(2):503-522. PubMed ID: 29388503
[TBL] [Abstract][Full Text] [Related]
16. Development of pharmacophore model to identify potential DNA gyrase inhibitors.
Jakhar R; Khichi A; Kumar D; Sura K; Bhoomika ; Dangi M; Chhillar AK
J Biomol Struct Dyn; 2023 Nov; 41(19):10125-10135. PubMed ID: 36473713
[TBL] [Abstract][Full Text] [Related]
17. Docking and 3D QSAR Studies on Substituted Cyclobutylphenyl Quinoline Derivatives as Inhibitors of Bacterial DNA Gyrase.
Wani RR; Chaudhari HK
Curr Comput Aided Drug Des; 2018; 14(4):322-337. PubMed ID: 29766821
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Medapi B; Renuka J; Saxena S; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 May; 23(9):2062-78. PubMed ID: 25801151
[TBL] [Abstract][Full Text] [Related]
19. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
20. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis.
Shirude PS; Madhavapeddi P; Tucker JA; Murugan K; Patil V; Basavarajappa H; Raichurkar AV; Humnabadkar V; Hussein S; Sharma S; Ramya VK; Narayan CB; Balganesh TS; Sambandamurthy VK
ACS Chem Biol; 2013 Mar; 8(3):519-23. PubMed ID: 23268609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
